Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $14.83

by · The Markets Daily

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $14.8333.

KPTI has been the subject of several research reports. Royal Bank Of Canada cut their price objective on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday, November 4th. Wall Street Zen raised Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday. Robert W. Baird reduced their price objective on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday, October 9th. Finally, Piper Sandler reiterated an “overweight” rating and set a $12.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th.

Get Our Latest Stock Report on Karyopharm Therapeutics

Karyopharm Therapeutics Trading Down 0.4%

Shares of Karyopharm Therapeutics stock opened at $7.44 on Wednesday. The stock has a market cap of $126.85 million, a PE ratio of -0.51 and a beta of 0.23. The company has a 50-day moving average of $6.10 and a two-hundred day moving average of $5.59. Karyopharm Therapeutics has a 12-month low of $3.51 and a 12-month high of $12.45.

Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($3.82) EPS for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The company had revenue of $44.04 million for the quarter, compared to analysts’ expectations of $39.56 million. On average, sell-side analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KPTI. Bank of America Corp DE raised its position in shares of Karyopharm Therapeutics by 26.8% in the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after buying an additional 35,626 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in Karyopharm Therapeutics in the 1st quarter valued at $523,000. Silverback Asset Management LLC raised its holdings in Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after acquiring an additional 20,000 shares during the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the second quarter worth $163,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the third quarter worth $164,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

(Get Free Report)

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.

Featured Stories